Hepatic steatosis in patients with HIV-Hepatitis C Virus coinfection: is it associated with antiretroviral therapy and more advanced hepatic fibrosis?

BMC Research Notes, Dec 2008

Background and aims Patients with HIV and hepatitis C virus (HCV) coinfection are at increased risk of developing hepatic steatosis. The aims of this study were to assess the prevalence of steatosis in a cohort with HIV-HCV coinfection, and to determine an association, if any, between steatosis, antiretroviral therapy (ART), and advanced hepatic fibrosis. Patients and methods HIV-HCV coinfected patients were retrospectively identified from the HIV clinic. ART was classified as none, nucleoside reverse transcriptase inhibitors (NRTIs) only, highly active antiretroviral therapy (HAART) only, and sequential therapy (initial NRTIs followed by HAART). Fibrosis stage and necroinflammation grade were assessed by the modified HAI (Ishak) scoring method. Steatosis was graded as 0–3. Results Sixty patients were identified. The overall prevalence of hepatic steatosis was 58%. Those that received HAART only had a lower prevalence of steatosis (41%) compared to those on NRTIs only (70%) or sequential therapy (82%). Independent predictors of hepatic steatosis were absence of HAART only therapy, OR 2.9, p = 0.09, and presence of cirrhosis, OR 4.6, p = 0.044. Forty five percent of the patients had advanced fibrosis (fibrosis stage ≥ 3). NI grade (OR 1.9, p = 0.030), and steatosis grade (OR 3.6, p = 0.045), were independent predictors of advanced fibrosis. Conclusion Hepatic steatosis is associated with more advanced hepatic fibrosis in the HIV-HCV coinfected population. HAART only therapy (rather than NRTIs only or sequential therapy) appears to be associated with a lower prevalence of hepatic steatosis. This may be one of the mechanisms by which HAART could attenuate hepatic fibrosis in such a cohort.

A PDF file should load here. If you do not see its contents the file may be temporarily unavailable at the journal website or you do not have a PDF plug-in installed and enabled in your browser.

Alternatively, you can download the file locally and open with any standalone PDF reader:

https://link.springer.com/content/pdf/10.1186%2F1756-0500-1-46.pdf

Hepatic steatosis in patients with HIV-Hepatitis C Virus coinfection: is it associated with antiretroviral therapy and more advanced hepatic fibrosis?

BMC Research Notes Short Report Hepatic steatosis in patients with HIV-Hepatitis C Virus coinfection: is it associated with antiretroviral therapy and more advanced hepatic fibrosis? Sumita Verma 1 Robert D Goldin 0 Janice Main 1 0 Department of Cellular Pathology, Imperial College at St Mary's Hospital , London , UK 1 Hepatology Section, Department of Medicine, Imperial College at St Mary's Hospital , London , UK Background and aims: Patients with HIV and hepatitis C virus (HCV) coinfection are at increased risk of developing hepatic steatosis. The aims of this study were to assess the prevalence of steatosis in a cohort with HIV-HCV coinfection, and to determine an association, if any, between steatosis, antiretroviral therapy (ART), and advanced hepatic fibrosis. Patients and methods: HIV-HCV coinfected patients were retrospectively identified from the HIV clinic. ART was classified as none, nucleoside reverse transcriptase inhibitors (NRTIs) only, highly active antiretroviral therapy (HAART) only, and sequential therapy (initial NRTIs followed by HAART). Fibrosis stage and necroinflammation grade were assessed by the modified HAI (Ishak) scoring method. Steatosis was graded as 0-3. Results: Sixty patients were identified. The overall prevalence of hepatic steatosis was 58%. Those that received HAART only had a lower prevalence of steatosis (41%) compared to those on NRTIs only (70%) or sequential therapy (82%). Independent predictors of hepatic steatosis were absence of HAART only therapy, OR 2.9, p = 0.09, and presence of cirrhosis, OR 4.6, p = 0.044. Forty five percent of the patients had advanced fibrosis (fibrosis stage ≥ 3). NI grade (OR 1.9, p = 0.030), and steatosis grade (OR 3.6, p = 0.045), were independent predictors of advanced fibrosis. Conclusion: Hepatic steatosis is associated with more advanced hepatic fibrosis in the HIV-HCV coinfected population. HAART only therapy (rather than NRTIs only or sequential therapy) appears to be associated with a lower prevalence of hepatic steatosis. This may be one of the mechanisms by which HAART could attenuate hepatic fibrosis in such a cohort. Introduction Highly active antiretroviral therapy (HAART) has significantly improved survival in patients with human immunodeficiency virus (HIV) infection [1]. Increasing attention is now being focused on co infection with other viruses like hepatitis C (HCV). Because of similar routes of transmission, approximately 25–30% of patients with HIV are also coinfected with HCV [2]. Factors associated with more advanced hepatic fibrosis in HCV infection include HIV coinfection [3] and hepatic steatosis, (prevalence of 47%–79%) [4-6]. Patients with HIV are also at increased risk of developing hepatic steatosis due to multiple factors including antiretroviral therapy (ART), obesity, hyperglycemia, lipodystrophy, and coinfection with HCV [ 2,7-11 ]. In HIV-HCV coinfection prevalence of hepatic steatosis varies between 40–72.1% [ 9-13 ]. In the coinfected population, the association between ART and steatosis, and whether steatosis is associated with advanced fibrosis remains controversial [ 9-11 ]. The aims of this study were therefore to assess whether in those with HIV-HCV coinfection 1. Use of ART is associated with hepatic steatosis 2. Hepatic steatosis is an independent predictor of advanced hepatic fibrosis 3. Hepatic steatosis is associated with fibrosis progression in serial liver biopsies Patients and methods The study period was from 1990–2005. Patients with HIV HCV coinfection were identified from the Pathology and HIV database after which, their charts and computerised chemical pathology and histology databases reviewed. To be included in the study the patients had to be 1. HCV antibody and or HCV PCR (qualitative) positive 2. HIV antibody positive 3. Have had a liver biopsy. The indications for a liver biopsy in most patients were abnormal liver tests. All the liver biopsies had been reviewed by RG who was blinded to the clinical information. The fibrosis stage (0–6) and necroinflammatory (NI) grade (0–18) were assessed by the modified HAI (Ishak) scoring system [ 14 ]. Steatosis was graded, (depending on % of hepatocytes containing fat), into grade 0 (< 5%), grade 1 (<33%), grade 2 (33%–66%), and grade 3 (>66%). HCV disease duration and fibrosis progression were calculated as before [ 15 ]. Lipoatrophy was stated to be present if mentioned in the patient records. Diabetes mellitus (DM) was defined by presence of one or more of the following: fasting blood glucose > 7 mmol/l, being on anti diabetic medications, and/or a note in the patient record stating that there was a history of DM. Anti-HCV antibody testing, HCV RNA and HIV RNA quantification and HCV genotyping were performed in the hospital virology laboratory using standard commercial kits (Abbott, Bayer, Roche). Alcohol abuse was defined as either consumption of > 3 units of alcohol/day (approximately 40 gms/day), an (...truncated)


This is a preview of a remote PDF: https://link.springer.com/content/pdf/10.1186%2F1756-0500-1-46.pdf

Sumita Verma, Robert D Goldin, Janice Main. Hepatic steatosis in patients with HIV-Hepatitis C Virus coinfection: is it associated with antiretroviral therapy and more advanced hepatic fibrosis?, BMC Research Notes, 2008, pp. 46, Volume 1, Issue 1, DOI: 10.1186/1756-0500-1-46